The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function

被引:33
作者
Yamamoto, N
Tamura, T
Maeda, M
Ando, M
Shinkai, T
Eguchi, K
Ohe, Y
Oshita, F
Shiraishi, J
Katsumata, N
Saijo, N
机构
[1] NATL CANC CTR,RES INST,DIV PHARMACOL,CHUO KU,TOKYO 104,JAPAN
[2] NATL CANC CTR,RES INST,CHEMOTHERAPY & DIV,CHUO KU,TOKYO 104,JAPAN
[3] NATL CANC CTR,DEPT MED ONCOL,CHUO KU,TOKYO 104,JAPAN
关键词
cisplatin; ageing; pharmacokinetics;
D O I
10.1007/BF00689192
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study was performed to identify any relationship between age and cisplatin (CDDP) pharmacokinetics in lung cancer patients. CDDP was given at a dose of 80 mg/m(2) by l-h intravenous infusion to 23 lung cancer patients. All patients had normal renal, hepatic, and bone marrow functions. We measured ultrafilterable platinum (U-Pt) and total plasma platinum (T-Pt) using atomic absorption spectrometry. There was significant correlation between the age of the patients and U-Pt pharmacokinetic parameters such as the area under the plasma concentration versus time curve (AUG), total clearance(Cl), and peak plasma concentration (Cmax) as well as the AUC of T-Pt (P < 0.05). We performed univariate regression analysis to examine the influence of factors aside from age on the AUC of U-Pt and T-Pt. Creatinine and GPT levels were significantly related to the AUC of U-Pt, and creatinine clearance and creatinine concentrations were significantly related to the AUC of T-Pt. Therefore, stepwise multiple-regression models for the AUC of U-Pt and T-Pt were developed to assess an age effect. Age was consistently an independent and significant predictor of the AUC of U-Pt and T-Pt.
引用
收藏
页码:102 / 106
页数:5
相关论文
共 12 条
[1]   RELATION BETWEEN AGE AND CLEARANCE RATE OF 9 INVESTIGATIONAL ANTICANCER DRUGS FROM PHASE-I PHARMACOKINETIC DATA [J].
BORKOWSKI, JM ;
DUERR, M ;
DONEHOWER, RC ;
ROWINSKY, EK ;
CHEN, TL ;
ETTINGER, DS ;
GROCHOW, LB .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 33 (06) :493-496
[2]  
BUNN PA, 1989, SEMIN ONCOL, V16, P10
[3]   DRUG-THERAPY - CLINICAL PHARMACOKINETICS .1. [J].
GREENBLATT, DJ ;
KOCHWESER, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 293 (14) :702-705
[4]   PHARMACOKINETIC STUDY OF MITOMYCIN-C WITH EMPHASIS ON THE INFLUENCE OF AGING [J].
MIYA, T ;
SASAKI, Y ;
KARATO, A ;
SAIJO, N .
JAPANESE JOURNAL OF CANCER RESEARCH, 1992, 83 (12) :1382-1385
[5]   TOXICITY AND RESPONSE CRITERIA OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP [J].
OKEN, MM ;
CREECH, RH ;
TORMEY, DC ;
HORTON, J ;
DAVIS, TE ;
MCFADDEN, ET ;
CARBONE, PP .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1982, 5 (06) :649-655
[6]  
POWIS G, 1985, CANCER CHEMOTH PHARM, V14, P177
[7]   CREATININE CLEARANCE AS A PREDICTOR OF ULTRAFILTERABLE PLATINUM DISPOSITION IN CANCER-PATIENTS TREATED WITH CISPLATIN - RELATIONSHIP BETWEEN PEAK ULTRAFILTERABLE PLATINUM PLASMA-LEVELS AND NEPHROTOXICITY [J].
REECE, PA ;
STAFFORD, I ;
RUSSELL, J ;
KHAN, M ;
GILL, PG .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (02) :304-309
[8]  
SCHMUCKER DL, 1985, PHARMACOL REV, V37, P133
[9]   PHARMACOKINETICS IN OLD-AGE [J].
TREGASKIS, BF ;
STEVENSON, IH .
BRITISH MEDICAL BULLETIN, 1990, 46 (01) :9-21
[10]  
WEINER MW, 1983, FED PROC, V42, P2974